These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10290754)

  • 41. The formulary decision-making process in a US academic medical centre.
    Nash DB; Catalano ML; Wordell CJ
    Pharmacoeconomics; 1993 Jan; 3(1):22-35. PubMed ID: 10146985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulary streamlining through therapeutic class review.
    Guerriero SE; Neff JL
    Hosp Pharm; 1995 Apr; 30(4):287-90. PubMed ID: 10141869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. P&T Committee overview: Brigham and Women's Hospital.
    Shea BF; Churchill WW; Powell SH; Cooley TW; Maguire JH
    Pharm Pract Manag Q; 1998 Jan; 17(4):76-83. PubMed ID: 10174751
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluating a restrictive formulary system by assessing nonformulary-drug requests.
    Green JA; Chawla AK; Fong PA
    Am J Hosp Pharm; 1985 Jul; 42(7):1537-41. PubMed ID: 4025350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chairman of the Joint Formulary Committee, British National Formulary.
    Kendall M
    Clin Med (Lond); 2009 Aug; 9(4):349-52. PubMed ID: 19728509
    [No Abstract]   [Full Text] [Related]  

  • 46. Multidisciplinary education ensures successful formulary conversion.
    Barfield PS; Amerson AB
    Hosp Formul; 1991 Nov; 26 Suppl D():28-9. PubMed ID: 10136563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibiotic review: the experience of one pharmacy and therapeutics committee.
    Kiepert DR
    QRB Qual Rev Bull; 1979 Jan; 5(1):24-7. PubMed ID: 121376
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacy and Therapeutics committee. Cost-containment considerations.
    Hochla PK; Tuason VB
    Arch Intern Med; 1992 Sep; 152(9):1773-5. PubMed ID: 1520043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of a selective restriction policy on antibiotic expenditure and use: an institutional model.
    Suwangool P; Moola-Or P; Waiwatana A; Sitthi-Amorn C; Israsena S; Hanvanich M
    J Med Assoc Thai; 1991 Jul; 74(7):272-5. PubMed ID: 1765742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Formulary evaluation of third-generation cephalosporins using decision analysis.
    Cano SB; Fujita NK
    Am J Hosp Pharm; 1988 Mar; 45(3):566-9. PubMed ID: 3285673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of ampicillin-sulbactam before and after formulary inclusion.
    Koch KE; Taylor MR
    Am J Hosp Pharm; 1991 Jul; 48(7):1492-6. PubMed ID: 1882880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Organization and operation of P & T Committees in the state of Florida: a survey.
    Hatton RC; Doering PL
    Hosp Formul; 1990 Sep; 25(9):983-6, 988-9. PubMed ID: 10106259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost containment efforts of a pharmacy and therapeutics committee.
    Slavick HE; Simon LS
    QRB Qual Rev Bull; 1984 Feb; 10(2):38-41. PubMed ID: 6424076
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmaceuticals in Australia: priorities in a teaching hospital.
    Kearney BJ
    Physician Exec; 1993; 19(5):63-7. PubMed ID: 10130953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 56. Developing a unit-of-use drug distribution system for the hospital emergency room.
    Schiavone JD
    Hosp Pharm; 1981 Apr; 16(4):208-9, 214-5, 219 passim. PubMed ID: 10251101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diffusion of innovation I: Formulary acceptance rates of new drugs in teaching and non-teaching British Columbia hospitals--a hospital pharmacy perspective.
    D'Sa MM; Hill DS; Stratton TP
    Can J Hosp Pharm; 1994 Dec; 47(6):254-60. PubMed ID: 10139270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Praxis makes perfect?
    Fins JJ
    Hastings Cent Rep; 1993; 23(5):16-9. PubMed ID: 7710462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-purpose evaluation of H2-antagonist usage.
    Gianarkis D
    Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.